Table 1.
Brachytherapy prioritization scale
| Priority | Indication | Modality | Action in the COVID-19 context |
|---|---|---|---|
| Priority 1 | Locally advanced cervical cancer | Boost | Do not postpone |
| Priority 2 | Head and neck (eg, lip) | Exclusive | Do not postpone |
| Skin or urogenital squamous cell carcinoma | Exclusive | ||
| Priority 3 | Pediatrics indication | Exclusive | To be discussed on an individual basis |
| Priority 4 | Intermediate and high risk prostate | Boost | Postpone (8-12 wk) or opt for external irradiation according to local facilities |
| Accelerated partial breast irradiation | Exclusive | ||
| High-risk endometrial cancer | Boost | ||
| Priority 5 | Low risk prostate | Exclusive | Postpone (8-12 wk) or opt for surveillance |
| Intermediate risk endometrial cancer | Exclusive | ||
| Priority 6 | Basal cell carcinoma | Exclusive | Postpone according to functional risks |
| Priority 7 | Endoscopic procedures (esophagus or bronchus) | Exclusive | Omit and consider external beam options |
| Priority 8 | Keloids | Exclusive | Omit and consider external beam options |
Abbreviation: COVID-19 = coronavirus disease 2019.